FDA Drug recall D-0869-2023
Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83
- FDA Drug
- Class II
- terminated
- Published 2023-06-14
On 2023-06-14 the FDA classified a Class II recall of Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83 by Sun Pharmaceutical Industries, citing CGMP Deviations.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0869-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2023-05-03 |
| Published | 2023-06-14 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Sun Pharmaceutical Industries |
| Distribution | US |
Product
Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.
Reason
CGMP Deviations
Identifiers
| ndc | 62756-459-83 |
|---|---|
| ndc | 62756-459-64 |
| ndc | 62756-460-83 |
| ndc | 62756-460-64 |
| code_info | Lot #: DND1515A, Exp 08/24 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0869-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.